Aldurazyme® (laronidase)

Aldurazyme (laronidase) is covered only for FDA‑approved MPS I indications — Hurler, Hurler‑Scheie, and Scheie with moderate‑to‑severe symptoms — and non‑FDA uses are excluded. Coverage requires documented deficient α‑L‑iduronidase activity or biallelic pathogenic IDUA variants, prescription/consultation with an appropriate specialist (geneticist, endocrinologist, metabolic disorder/lysosomal storage disorder specialist), adherence to the 0.58 mg/kg IV weekly dosing, documentation of subtype/severity (for Scheie), and is authorized for up to 12 months.

"Treatment of individuals with the Hurler form of mucopolysaccharidosis type I (MPS I) (FDA-approved)."

Sign up to see full coverage criteria, indications, and limitations.